Quest Diagnostics
1,067 hedge funds and large institutions have $20.1B invested in Quest Diagnostics in 2026 Q1 according to their latest regulatory filings, with 123 funds opening new positions, 351 increasing their positions, 381 reducing their positions, and 88 closing their positions.
139% more call options, than puts
Call options by funds: $96.9M | Put options by funds: $40.5M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
40% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 88
9% more capital invested
Capital invested by funds: $18.4B → $20.1B (+$1.67B)
2% more funds holding
Funds holding: 1,050 → 1,067 (+17)
8% less repeat investments, than reductions
Existing positions increased: 351 | Existing positions reduced: 381
2.21% less ownership
Funds ownership: 95.56% → 93.34% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$113M |
| 2 |
MDSL
M.D. Sass LLC
New York
|
+$58.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$49M |
| 4 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$45.7M |
| 5 |
Barclays
London,
United Kingdom
|
+$45.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$80.1M |
| 2 |
Goldman Sachs
New York
|
-$70M |
| 3 |
FMI
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
-$63.3M |
| 4 |
FGP
Freestone Grove Partners
San Francisco,
California
|
-$59M |
| 5 |
JP Morgan Chase
New York
|
-$58.2M |
DGX Hedge Fund Activity: Q1 2026 in Review
1,067 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2026, worth a combined $20.1B — up 9.1% from $18.4B a quarter earlier.
Buyers outnumbered sellers: 123 funds opened new DGX positions and 88 closed out — a net gain of 35 holders — while 351 added to existing stakes and 381 trimmed.
The largest buyer was EdgePoint Investment Group, adding an estimated $113M. The largest seller was UBS Group, cutting an estimated $80.1M.
- 1,067 institutional investors held Quest Diagnostics (DGX) as of Q1 2026, up from 1,050 in Q4 2025.
- Funds reported $20.1B of Quest Diagnostics stock for Q1 2026, up 9.1% quarter-over-quarter.
- 123 funds opened new Quest Diagnostics positions in Q1 2026 and 88 closed out, a net change of +35 holders.
- The largest Quest Diagnostics buyer in Q1 2026 was EdgePoint Investment Group, an estimated $113M added.
- The largest Quest Diagnostics seller in Q1 2026 was UBS Group, an estimated $80.1M sold.
Based on aggregated 13F filings for Q1 2026.